Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.